Mary Ellen Coe Purchases Merck Shares
Mary Ellen Coe buys 234 shares of Merck, highlighting insider interest.
Key Points
- Mary Ellen Coe bought 234 shares of Merck & Co., Inc. (NYSE:MRK) at $128.5 per share on June 30, 2026, totaling $30,069.
- Merck's stock traded near $128.5 on Wednesday, with a market cap of $317.4 billion and a P/E ratio of 36.2.
- Analysts from B of A Securities and Scotiabank maintained buy ratings with targets as high as $155.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Mary Ellen Coe, an insider at Merck & Co., Inc. (NYSE:MRK), purchased 234 shares of the company. The shares were bought at $128.5 each, bringing the total transaction value to $30,069. This move adds to the interest in Merck from insiders.
Insider Buying and Selling at Merck & Co., Inc.
In addition to Mary Ellen Coe's purchase, several other insiders also bought shares. On the same day, Christine Seidman acquired 63 shares, and Surendralal Lanca bought 127 shares, both at $128.5 per share. Earlier, on May 29, Kathy Warden, Paul Rothman, and Christine Seidman purchased 1,853 shares each at a lower price of $118.72.
Merck & Co., Inc. Stock Down 13.4%
Shares of NYSE:MRK traded near $128.5 on Wednesday. Merck & Co., Inc. boasts a market capitalization of approximately $317.4 billion. The company has a P/E ratio of 36.2 and a forward P/E of 13.4, with a beta of 0.218, indicating lower volatility compared to the market. The stock's 52-week range is between $76.66 and $130.29, with a 50-day moving average of $116.12 and a 200-day moving average of $106.56.
$MRK stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 30, 2026, B of A Securities maintained its buy rating on Merck, setting a price target of $141. Scotiabank also maintained a buy rating, with a target of $155. Earlier, on June 24, CICC initiated coverage with a buy rating and a $138 target. Overall, the consensus among analysts is a buy rating, with a mean price target of $130.39 across 28 opinions.
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare company headquartered in Rahway, New Jersey. It operates in the drug manufacturing industry, providing pharmaceuticals for human health under well-known brands like Keytruda and Gardasil. The company also offers veterinary products and health management solutions. Led by CEO Robert M. Davis, Merck employs around 73,000 people worldwide.
Bottom Line
Mary Ellen Coe's purchase of Merck shares underscores ongoing insider interest in the company. Merck remains a significant player in the healthcare sector, with a strong market presence and a solid financial position. Investors keep a close eye on insider transactions as they can provide insights into the company's prospects. Remember, insider trading reports like these are backward-looking and reflect past actions, not necessarily current or future intentions.
Get Merck & Co., Inc. alerts
New 13F filings, insider trades, and analyst moves on $MRK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.